David Cherney, MD, PhD, is Professor of Medicine and Gabor Zellerman Chair of Nephrology Research, University of Toronto. He is a Clinician Scientist in the Division of Nephrology at the University Health Network and Mount Sinai Hospitals and Director of the Renal Physiology Laboratory at UHN.

Kidney Compass: REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD

At the World Congress of Nephrology 2026 in Yokohama, Japan, growing attention is being paid not just to whether therapies improve outcomes in chronic kidney disease, but how they work at a mechanistic level. In this episode of 

, host Brendon Neuen, MBBS, PhD, spoke with David Cherney, MD, PhD, about the REMODEL trial, a mechanistic study designed to better understand the kidney-protective effects of semaglutide in patients with type 2 diabetes and chronic kidney disease.

As Cherney explained during the discussion, REMODEL was conceived as a companion to the landmark FLOW trial, which demonstrated significant reductions in cardiorenal outcomes with semaglutide. While FLOW established clinical efficacy, Cherney emphasized that REMODEL was designed to answer a different question: why these benefits occur. Both he and Neuen highlighted that prior analyses suggested the observed kidney protection could not be fully explained by traditional risk factor improvements such as glycemic control, weight loss, or blood pressure reduction.

To address this, Cherney described how REMODEL incorporated a range of advanced imaging and biomarker-based endpoints. The primary outcome focused on MRI-derived measures of kidney oxygenation, while secondary endpoints included albuminuria, kidney function, and a suite of mechanistic markers such as fibrosis, intrarenal fat, and inflammatory pathways. A subset of participants also underwent paired kidney biopsies, allowing for direct assessment of cellular and molecular changes within the kidney.

According to Cherney, the trial did not demonstrate an effect on kidney oxygenation, but did reveal several other important mechanistic signals. He noted that semaglutide led to a reduction in perirenal and hilar fat, a finding that Neuen highlighted as particularly intriguing given emerging hypotheses around the role of local adiposity in kidney injury. Cherney also pointed to improvements in markers of fibrosis and inflammation, including changes in endothelial cell biology and reductions in inflammatory cell populations, suggesting a direct intrarenal effect.

The conversation explored these findings in greater depth, with Neuen raising the possibility that perirenal fat may contribute to kidney injury through both mechanical and inflammatory mechanisms. In response, Cherney outlined multiple potential pathways, including physical compression of renal structures and the metabolic activity of adipose tissue driving cytokine-mediated injury. Both emphasized that these hypotheses warrant further investigation but may represent an underappreciated contributor to disease progression.

Clinically, Cherney reported that semaglutide reduced albuminuria by approximately 40%, reinforcing its potential as a kidney-protective therapy. He also presented subgroup analyses from the REMODEL trial showing consistent effects regardless of baseline use of SGLT2 inhibitors. Neuen noted that this finding aligns with broader evidence suggesting additive and complementary mechanisms between these drug classes, supporting their combined use in high-risk patients.

Looking ahead, both speakers emphasized the broader implications of these findings. Cherney suggested that the mechanisms observed in REMODEL, particularly those related to inflammation and endothelial dysfunction, are likely not specific to diabetes and may extend to non-diabetic kidney disease. He also stressed the importance of reframing semaglutide as a kidney-directed therapy, independent of its effects on glucose or weight, a point Neuen reinforced as critical for both clinicians and patients.

Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Relevant disclosures for Cherney include Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Abbvie, Janssen, AMGEN, Bayer, , Gilead, CSL-Behring, Otsuka, Novartis, GSK, and others.

Podcasts

David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Martin de Borst, MD, PhD, is consultant nephrologist at the University Medical Center Groningen and adjunct professor of medicine at the University of Groningen.

Kidney Compass: IV Iron and Functional Outcomes in Kidney Transplant Recipients

Iron deficiency is increasingly recognized as a clinically meaningful yet underexplored contributor to morbidity in kidney disease, extending beyond its traditional association with anemia. In populations such as kidney transplant recipients, where graft function may be stable, many patients continue to experience impaired physical function, reduced quality of life, and lingering fatigue.

As evidence from other fields, particularly cardiology, has begun to demonstrate the benefits of intravenous iron on functional outcomes independent of hemoglobin, questions are emerging about whether similar strategies could improve how patients with kidney disease feel and function, not just how they measure on laboratory parameters.

In this episode of Kidney Compass recorded on-site at World Congress of Nephrology in Yokohama, Japan, hosts Shikha Wadhwani, MD, MS, and Brendon Neuen, MBBS, PhD, spoke with Martin de Borst, MD, PhD, about his investigator-initiated randomized trial of intravenous iron in kidney transplant recipients.

Throughout the conversation, de Borst emphasized that the study was motivated by a gap between clinical perception and patient experience. While kidney transplant recipients are often thought to do well, he noted that a subset of patients continue to experience reduced exercise capacity, approximately 20% lower than healthy individuals on average. At the same time, iron deficiency remains common in this population, affecting roughly 1 in 5 patients.

Drawing on prior observational work, de Borst explained that iron deficiency had been associated with worse outcomes across multiple domains, including physical function, quality of life, and cognitive performance, raising the question of whether these relationships were causal.

Neuen reinforced that iron’s biological role extends well beyond erythropoiesis, highlighting its importance in mitochondrial function and muscle performance, while Wadhwani underscored the novelty of focusing on functional endpoints rather than traditional kidney metrics. As de Borst described, the trial was designed with a primary endpoint of the 6-minute walk test, selected for its practicality and reproducibility in a multicenter setting, alongside a broad range of secondary outcomes including neurocognitive testing, quality of life assessments, and cardiac imaging.

The study enrolled 148 stable kidney transplant recipients with iron deficiency, irrespective of hemoglobin levels, and randomized them to receive intravenous ferric carboxymaltose or placebo over a 24-week period. According to de Borst, the results showed modest improvements in exercise capacity. Of note, these improvements were observed in both the treatment and placebo groups, with no significant difference between them. He further noted that secondary outcomes, including cognitive function, cardiac parameters, and quality of life, were similarly neutral.

Despite these findings, de Borst pointed out that biochemical markers of iron status improved substantially in the treatment arm, indicating that while iron stores were corrected, this did not translate into measurable clinical benefit in this population. He also highlighted a small, unexpected signal suggesting a potential improvement in kidney function, though he cautioned that this finding requires further investigation.

The discussion then turned to how these results should be interpreted. Neuen raised the possibility of a ceiling effect, noting that patients in the trial were relatively high functioning at baseline, which may have limited the ability to detect meaningful improvements. De Borst agreed, explaining that while participants had some impairment compared with predicted values, they were not as severely affected as populations in which intravenous iron has shown benefit, such as heart failure.

Looking back, de Borst reflected that selecting a more symptomatic population or one with greater baseline functional limitation may have yielded different results. Both hosts emphasized that this highlights the challenges of trial design in relatively stable transplant populations and the importance of aligning endpoints with patient characteristics.

The conversation expanded beyond the trial itself to broader implications for the field. Neuen stressed that unlike cardiology, where intravenous iron has demonstrated benefits on functional outcomes, nephrology has remained largely focused on hemoglobin-based endpoints. He and de Borst both suggested that this paradigm may need to shift, particularly in non-dialysis chronic kidney disease populations where symptom burden is high and data on patient-centered outcomes remain limited.

Wadhwani echoed this perspective, noting the growing need to better understand how therapies impact how patients feel and function, not just traditional laboratory measures.

Editors’ note: Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Relevant disclosures for Wadhwani include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. De Borst reports no relevant disclosures.

Martin de Borst, MD, PhD, discusses IV iron use in transplant recipients through an RCT focused on exercise capacity, function, and quality of life.

Katherine Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington.

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

Chronic kidney disease (CKD) in the setting of type 2 diabetes represents one of the most high-risk clinical scenarios in medicine, driven not only by progression to kidney failure but by a substantial burden of cardiovascular morbidity and premature death.

While recent therapeutic advances have improved outcomes, understanding how these treatments exert their benefits has remained a critical gap. The REMODEL trial was designed to address this question, offering a detailed mechanistic complement to landmark outcome data on semaglutide’s benefit in this patient population.

 at the World Congress of Nephrology (WCN) in Yokohama, Japan, Katherine Tuttle, MD, explained that REMODEL builds on the success of the FLOW trial, which demonstrated significant reductions in kidney events, cardiovascular outcomes, and all-cause mortality with semaglutide, ultimately leading to the agent’s US Food and Drug Administration approval for this indication. While those findings established clinical efficacy, they did not fully explain the underlying biology. REMODEL, she explains, was specifically designed as a mechanistic “deep dive,” integrating advanced imaging, kidney biopsy, and transcriptomic analyses to uncover how these benefits are achieved.

The study confirmed key clinical findings, including a 40% reduction in albuminuria and stabilization of kidney function. Of note, functional MRI revealed significant reductions in kidney fat far exceeding overall weight loss as well as improved vascular health, reflected by decreased renal arterial resistance. Markers of fibrosis progression were halted in the treatment group, suggesting a protective structural effect.

Biopsy data provided further depth. Tuttle highlights a marked reduction in peri-glomerular immune cells, particularly natural killer T cells, alongside broad downregulation of fibroinflammatory pathways, pointing to a direct anti-inflammatory effect within the kidney microenvironment. Transcriptomic analyses additionally identified glomerular endothelial cells as a key site of regulation, supporting the concept of improved integrity of the glomerular filtration barrier and even evidence of repair, not just stabilization, over time.

She emphasizes that these results align closely with preclinical models, strengthening confidence in translational research approaches. Beyond individual findings, the study design itself represents a major advance, demonstrating that rigorous mechanistic trials can be successfully conducted in humans.

Looking ahead, Tuttle underscores the implications for precision medicine. While current therapies are broadly applied, variability in response remains a major challenge. By linking mechanistic signatures to treatment outcomes, REMODEL provides a framework for identifying responders and tailoring therapy. Ultimately, she suggests, this approach could shift care toward selecting the right treatment for the right patient at the right time, marking a significant step forward in the management of diabetic kidney disease.

Editors’ note: relevant disclosures for Tuttle include Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk, Travere Therapeutics, and Bayer.

Campbell P. Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial. HCPLive. March 5, 2024. Accessed March 31, 2026. 

https://www.hcplive.com/view/semaglutide-1-0-mg-ozempic-reduced-kidney-events-24-in-flow-trial

Brooks A. FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease. HCPLive. January 28, 2025. Accessed March 31, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-ozempic-type-2-diabetes-chronic-kidney-disease

Pruijm M, Belmar N, Bjornstad P, et al. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. 

Videos

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

TRACE: Tralokinumab Data for Atopic Dermatitis in Skin of Color, With April Armstrong, MD, MPH

A new post-hoc analysis from the TRACE study suggests 80.4% of patients with skin of color and atopic dermatitis who were involved in the study achieved at least 1 clinically meaningful disease control endpoint at 12 months of use.

This post-hoc analysis was 1 of several from the TRACE study presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

. The data was authored by investigators such as April Armstrong, MD, MPH, of UCLA’s David Geffen School of Medicine, who spoke with 

 about these new findings on tralokinumab, providing important real-world insights into the long-term effectiveness of tralokinumab in adults with atopic dermatitis.

“The TRACE study is a real world study looking at patients with moderate to severe atopic dermatitis who started on tralokinumab, and the unique aspect about this particular study is that it recruited globally and [used] a patient population,” Armstrong explained.

The study is a prospective, non-interventional, international study designed to assess outcomes over 12 months in those using tralokinumab in routine clinical practice. In 1 piece of data highlighted at the meeting, patients with baseline head and neck involvement (n=495) saw substantial and sustained disease improvement over time.

Specifically, the proportion of those reporting any head and neck involvement dipped from baseline to 46.3% at Month 3 and dipped further to 31.6% at Month 12. The investigators noted such improvements were accompanied by early and clinically meaningful gains in symptom burden and disease severity, including reductions in Peak Pruritus and Sleep Numerical Rating Scale (PP/Sleep-NRS) scores, Investigator’s Global Assessment (IGA) scores, and Dermatology Life Quality Index (DLQI) score improvements.

In the separate subgroup analysis described by Armstrong, regarding 131 patients with skin of color (Fitzpatrick skin types IV–VI), 80.4% attained at least a single clinically meaningful disease control endpoint by the 12-month mark. These endpoints included IGA 0/1, EASI ≤7, or SCORAD <10, suggesting minimal to mild disease. Observance of quality of life improvements also took place in this population.

“What we found is that, among patients who were classified as skin of color, about 80% of them are able to achieve that stringent endpoint by 12 months,” Armstrong said. “And importantly, for that particular endpoint looking at the difference between, for example, patients who are skin of color with the overall population, the difference was actually very small.”

Across the overall study population (n=824), Armstrong et al found 91% of patients achieved at least 1 moderate treatment target after 12 months of tralokinumab use. Notably, approximately three-quarters met both clinician-reported and patient-reported moderate endpoints. The team also found nearly half attained optimal targets consistent with minimal disease activity.

For any additional information on these data, view Armstrong’s full interview posted above.

The quotes used in this summary were edited for clarity.

Armstrong has served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026. LEO Pharma. May 30, 2026. 

https://www.businesswire.com/news/home/20260328143419/en/LEO-Pharma-Presents-New-12-Month-Real-World-Data-for-Tralokinumab-at-AAD-2026

Armstrong AW, Rubin C, Jarell A, et al. Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: final data from the prospective, non-interventional, international TRACE study. Presented at the 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO. Poster ID: 77199. Oral Poster Presentation.

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Upadacitinib is both safe and effective over 48 weeks among patients with 

, new findings suggest, with no new safety signals or major adverse cardiovascular events (MACE) identified.

These late-breaking data, the result of the Viti-Up-1 and Viti-Up-2 studies, were released during the 

 editorial team spoke on-site with trial investigator Thierry Passeron, MD, PhD, professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

“Unfortunately, so far, there is no systemic treatment approved for vitiligo, and there is still a high unmet need for the patients suffering from vitiligo,” Passeron explained.

Non-segmental vitiligo, an autoimmune inflammatory disease impacting the skin, is characterized by patients’ loss of melanocytes. This can lead to unpredictable skin depigmentation. Passeron stressed the lack of systemic medications approved for the condition, describing additional options as necessary.

Passeron and colleagues reported in this study on the efficacy and safety of upadacitinib, a selective once-daily Janus kinase (JAK) 1 inhibitor, 15 mg in adults and adolescents with non-segmental vitiligo. It was studied across 48 weeks in this pair of identical, pivotal phase 3 analyses.

In his interview, Passeron noted most of the patients were Fitzpatrick skin types 3 and 4, further describing those treated with upadacitinib in the study as being a severe disease population. The subjects were both adults and adolescents aged ≥ 12 years with this skin disease involving the face and body.

They all had a Facial Vitiligo Scoring Index (F-VASI) ≥ 0·5 and a Total Vitiligo Area Scoring Index (T-VASI) ≥ 5. The subjects were randomized 2:1 to be treated either with upadacitinib 15 mg or placebo once daily. There were 614 individuals involved across Viti-Up-1 (n=308) and Viti-Up-2 (n=306) in total.

“Two-thirds of the population were active, and three-fourths had T-VASI above 10…and the mean duration of the vitiligo was about 15 years,” Basseron said. “Most of them had vitiligo that had already been treated by topical treatment of phototherapy.”

In this poster at AAD, the treatment with upadacitinib was described as providing clinically meaningful repigmentation among adult and adolescent patients with non-segmental vitiligo.

 Passeron and coauthors’ safety data through week 48 were described as consistent with the overall profile for upadacitinib.

Specifically, they noted a lack of reports of adjudicated MACE, adjudicated gastrointestinal (GI) perforations, adjudicated venous thromboembolic events (VTE), lymphoma, active tuberculosis, non-melanoma skin cancer, or opportunistic infections outside of herpes zoster in either analysis.

 Among the most often reported TEAEs, examples included acne, upper respiratory infection, nasopharyngitis, and headache. There were 4 serious infections reported among patients in the Viti-Up-1 upadacitinib cohort, though none led to treatment cessation.

For any additional information on the new data from the Viti-Up-1 and 2 trials, view the full video with Passeron posted above.

Passeron is a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Calypso, Galderma, Incyte Corporation, Janssen, Eli Lilly, Novartis, Pfizer, Roivant, UCB, and VYNE Therapeutics. He has received grants and/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/Sanofi, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Roivant, Sun Pharmaceuticals, Takeda, UCB, and VYNE Therapeutics. He is the cofounder of NIKAIA Pharmaceuticals and founder of SUNLUTION, and has patents on WNT agonists or GSK3b antagonist for repigmentation of vitiligo and the use of CXCR3B blockers in vitiligo.

Passeron T, Prajapati V, Seneschal J, et al. Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up). Presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO.

Smith T. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo. HCPLive. February 3, 2026. Accessed March 30, 2026. 

https://www.hcplive.com/view/upadacitinib-regulatory-applications-submitted-adults-adolescents-vitiligo

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Your Patient's New Therapist Is an AI. Now What?

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Articles

New information from the phase 3 SCOUT-HCM trial indicate the benefits of mavacamten may extend to adolescents as well as adults. 

Cardiomyopathy

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Mavacamten Shows Benefit for Pediatric Patients in SCOUT-HCM Trial

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.

VALOR: Brepocitinib AAD Data Support Priority Review for Dermatomyositis

Nicholas Marston, MD, MPH, is a cardiologist and an assistant professor of medicine at Brigham and Women's Hospital.

Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.

Atherosclerotic Cardiovascular Disease

Strategic Alliance Partnership

Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH

Layla Van Doren, MD, MBA, is an assistant professor of medicine at Yale School of Medicine and a classical hematologist at Smilow Cancer Hospital.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Burnout in Sickle Cell Physicians Hits 60% While Grit and Resilience Stand Strong

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Video Series

Evaluating Treatment Selection in Psoriasis

Luisa Campos, Global Heme Lead, Medical & Scientific Affairs at Thermo Fisher Scientific.

Rapid NGS and streamlined workflows are critical to delivering timely, actionable genomic insights in blood cancers, but access, reimbursement, and expertise gaps persist.

Timing Is Everything: Advancing Genomic Testing in Hematologic Malignancies

Understanding the Psoriasis Treatment Landscape and Available IL-23 Inhibitors

This interview with David Cotter, MD, PhD, highlights recent findings and new data in the psoriasis treatment space highlighted at AAD 2026.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Latest News

Kidney Compass: REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD

Kidney Compass: IV Iron and Functional Outcomes in Kidney Transplant Recipients

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

TRACE: Tralokinumab Data for Atopic Dermatitis in Skin of Color, With April Armstrong, MD, MPH

Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD